# EDGAR Filing Document

**Accession Number:** 0001341235
**File Stem:** 0001193125-26-083135
**Filing Date:** 2026-2
**Character Count:** 14008
**Document Hash:** c9237882a7b5053cfbb787e45e47b316
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-083135.hdr.sgml**: 20260227

**ACCESSION NUMBER**: 0001193125-26-083135

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 17

**FILED AS OF DATE**: 20260227

**DATE AS OF CHANGE**: 20260227

**EFFECTIVENESS DATE**: 20260227

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Aldeyra Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001341235
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-293882
- **FILM NUMBER:** 26701589

**BUSINESS ADDRESS:**
- **STREET 1:** 131 HARTWELL AVENUE
- **STREET 2:** SUITE 320
- **CITY:** LEXINGTON
- **STATE:** MA
- **ZIP:** 02421
- **BUSINESS PHONE:** 781-761-4904

**MAIL ADDRESS:**
- **STREET 1:** 131 HARTWELL AVENUE
- **STREET 2:** SUITE 320
- **CITY:** LEXINGTON
- **STATE:** MA
- **ZIP:** 02421

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Aldexa Therapeutics, Inc.
- **DATE OF NAME CHANGE:** 20130102

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Neuron Systems Inc
- **DATE OF NAME CHANGE:** 20051012

**As filed with the Securities and Exchange Commission on February 27, 2026** 

**Registration No. 333-** 

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**FORM S-8** 

**REGISTRATION STATEMENT** 

***UNDER***

***THE SECURITIES ACT OF 1933***

## ALDEYRA THERAPEUTICS, INC.
**(Exact name of registrant as specified in its charter)** 

---

| | |
|:---|:---|
| **Delaware** | **20-1968197** |
| **(State or other jurisdiction of**<br> **incorporation or organization)** | **(I.R.S. Employer**<br> **Identification No.)** |
| **131 Hartwell Avenue, Suite 320**<br> **Lexington, MA** | **02421** |
| **(Address of Principal Executive Offices)** | **(Zip Code)** |

---

**2016 Employee Stock Purchase Plan** 

**(Full title of plan)** 

**Todd C. Brady, M.D., Ph.D.,** 

**President and Chief Executive Officer** 

**131 Hartwell Avenue, Suite 320** 

**Lexington, MA 02421** 

**(Name and address of agent for service)** 

**(781) 761-4904** 

**(Telephone number, including area code, of agent for service)** 

***Please send copies of all communications to:***

**Keith J. Scherer** 

**Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP** 

**One Marina Park Drive, Suite 900** 

**Boston, MA 02210** 

**Telephone: (617) 648-9100** 

**Telecopy: (617) 648-9199** 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
|  |  | Emerging growth company | ☐ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

------

**PART I** 

**EXPLANATORY NOTE** 

**INFORMATION REQUIRED IN THE SECTION 10(A) PROSPECTUS** 

This Registration Statement on Form S-8 registers additional shares of Common Stock to be issued pursuant to the Purchase Plan. The information contained in the Registrant's registration statements on Form S-8 (SEC File Nos. [333-230161](http://www.sec.gov/Archives/edgar/data/1341235/000119312519069189/d716947ds8.htm), [333-224019](http://www.sec.gov/Archives/edgar/data/1341235/000119312518102096/d545154ds8.htm), [333-217043](http://www.sec.gov/Archives/edgar/data/1341235/000119312517104243/d368263ds8.htm), [333-213045](http://www.sec.gov/Archives/edgar/data/1341235/000119312516677537/d153477ds8.htm), [333-237129](http://www.sec.gov/Archives/edgar/data/1341235/000119312520071672/d847470ds8.htm), [333-254144](http://www.sec.gov/Archives/edgar/data/1341235/000119312521077845/d152129ds8.htm), [333-263660](http://www.sec.gov/Archives/edgar/data/1341235/000119312522078435/d335510ds8.htm), [333-270401](http://www.sec.gov/Archives/edgar/data/1341235/000119312523066127/d675707ds8.htm), [333-277752](http://www.sec.gov/Archives/edgar/data/1341235/000119312524062277/d748506ds8.htm) and [333-285460](http://www.sec.gov/Archives/edgar/data/1341235/000119312525042772/d892172ds8.htm)), together with all exhibits filed therewith or incorporated therein by reference, are hereby incorporated by reference pursuant to General Instruction E to Form S-8.

------

**PART II** 

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT** 

**Item 8. <u>Exhibits.</u>** 

**EXHIBIT INDEX** 

---

| | |
|:---|:---|
| **Exhibit<br>Number** | **Description of Exhibit** |
| 5.1\* | [Opinion of Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP.](d103363dex51.htm) |
| 23.1\* | [Consent of BDO USA, P.C., independent registered public accounting firm.](d103363dex231.htm) |
| 23.2\* | [Consent of Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP (included in Exhibit 5.1).](d103363dex51.htm) |
| 24.1\* | [Power of Attorney (included in the signature page to the registration statement).](#sig) |
| 107\* | [Filing Fee Table.](d103363dexfilingfees.htm) |

---

\* Filed herewith.

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Lexington, Commonwealth of Massachusetts, on this 27th day of February, 2026.

---

| |
|:---|
| **ALDEYRA THERAPEUTICS, INC.** |
| /s/ Todd C. Brady, M.D., Ph.D. |
| **Todd C. Brady, M.D., Ph.D.** |
| **President and Chief Executive Officer** |

---

------

**POWER OF ATTORNEY** 

**KNOW ALL PERSONS BY THESE PRESENTS**, that the undersigned officers and directors of Aldeyra Therapeutics, Inc., a Delaware corporation, do hereby constitute and appoint Todd C. Brady, M.D., Ph.D. and Michael Alfieri, and each of them, the lawful attorneys-in-fact and agents with full power and authority to do any and all acts and things and to execute any and all instruments which said attorneys and agents, and any one of them, determine may be necessary or advisable or required to enable said corporation to comply with the Securities Act, and any rules or regulations or requirements of the Securities and Exchange Commission in connection with this Registration Statement. Without limiting the generality of the foregoing power and authority, the powers granted include the power and authority to sign the names of the undersigned officers and directors in the capacities indicated below to this Registration Statement, to any and all amendments, both pre-effective and post-effective, and supplements to this Registration Statement, and to any and all instruments or documents filed as part of or in conjunction with this Registration Statement or amendments or supplements thereof, and each of the undersigned hereby ratifies and confirms that all said attorneys and agents, or any one of them, shall do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons on behalf of the Registrant in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| Signature | Title | Date |
| /s/ Todd C. Brady, M.D., Ph.D.<br> Todd C. Brady, M.D., Ph.D. | President, Chief Executive Officer and Director<br> (Principal Executive Officer) | February 27, 2026 |
| /s/ Michael Alfieri<br> Michael Alfieri | Head of Finance<br> (Principal Financial and Accounting Officer) | February 27, 2026 |
| /s/ Richard H. Douglas, Ph.D.<br> Richard H. Douglas, Ph.D. | Chairman of the Board of Directors | February 27, 2026 |
| /s/ Ben Bronstein, M.D.<br> Ben Bronstein, M.D. | Director | February 27, 2026 |
| /s/ William D. Clark<br> William D. Clark | Director | February 27, 2026 |
| /s/ Martin J. Joyce<br> Martin J. Joyce | Director | February 27, 2026 |
| /s/ Nancy Miller-Rich<br> Nancy Miller-Rich | Director | February 27, 2026 |
| /s/ Gary Phillips, M.D.<br> Gary Phillips, M.D. | Director | February 27, 2026 |
| /s/ Neal Walker, D.O.<br> Neal Walker, D.O. | Director | February 27, 2026 |

---

## Exhibit 5.1

**Exhibit 5.1**![LOGO](g103363dsp007.jpg)

February 27, 2026

Aldeyra Therapeutics, Inc.

131 Hartwell Avenue, Suite 320

Lexington, MA 02421

Re: Aldeyra Therapeutics, Inc. Registration Statement on Form S-8 for 601,628 Shares of Common Stock

Ladies and Gentlemen:

We refer to the registration statement on Form S-8 (the "Registration Statement") to be filed by Aldeyra Therapeutics, Inc., a Delaware corporation (the "Company"), with the Securities and Exchange Commission (the "Commission") in connection with the registration under the Securities Act of 1933, as amended (the "Act") of 601,628 shares of the Company's common stock, $0.001 par value per share (the "Common Stock" and such shares the "Shares") issuable in the aggregate under the Company's 2016 Employee Stock Purchase Plan (the "ESPP").

As your counsel, we have examined such matters of fact and questions of law as we have deemed necessary in order to render the opinion set forth herein. In connection with our opinion expressed below, we have relied as to certain factual matters on information obtained from public officials, officers of the Company and other sources believed by us to be responsible. We express no opinion as to matters governed by any laws other than the laws of the Delaware General Corporation Law and the federal laws of the United States.

Based upon and subject to the foregoing, we advise you that, in our opinion, when the Shares have been issued and sold pursuant to the applicable provisions of the ESPP, and in accordance with the Registration Statement, such Shares will be validly issued, fully paid and non-assessable shares of the Company's Common Stock.

We hereby consent to the filing of this opinion as an exhibit to the Registration Statement. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Act or the rules and regulations of the Commission thereunder.

Very truly yours,

---

| |
|:---|
| /s/ Gunderson Dettmer Stough Villeneuve<br> Franklin & Hachigian, LLP |
| Gunderson Dettmer Stough Villeneuve<br> Franklin & Hachigian, LLP |

---

![LOGO](g103363dsp007b.jpg)

![LOGO](g103363dsp007aa.jpg)

## Exhibit 23.1

**Exhibit 23.1** 

<u>Consent of Independent Registered Public Accounting Firm</u> 

We hereby consent to the incorporation by reference in this Registration Statement of our report dated February 27, 2026, relating to the consolidated financial statements of Aldeyra Therapeutics, Inc. (the Company) appearing in the Company's Annual Report on Form 10-K for the year ended December 31, 2025.

/s/ BDO USA, P.C.

Boston, Massachusetts

February 27, 2026

## Ex-Filing

?xml version='1.0' encoding='ASCII'? EX-FILING FEES

---

| |
|:---|
| **Calculation of Filing Fee Tables**  |
| &nbsp;&nbsp;&nbsp;&nbsp;**S-8**  |
| &nbsp;&nbsp;&nbsp;&nbsp;**Aldeyra Therapeutics, Inc.**  |

---

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Security Type**  | **Security Class Title**  | **Fee Calculation Rule**  | **Amount Registered**  | **Proposed Maximum Offering Price Per Unit**  | **Maximum Aggregate Offering Price**  | **Fee Rate**  | **Amount of Registration Fee**  |
| 1 | Equity | Common Stock, $0.001 par value per share, reserved for issuance pursuant to the 2016 Employee Stock Purchase Plan | Other | 601628 | $4.233 | $2546691.33 | 0.0001381 | $351.70 |
| Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: |  | $2546691.33  |  | $351.70  |
| Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  |  |  |  | $0.00  |
| Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  |  |  |  | $351.70  |

---

 **Offering Note** <br>

<sup>1</sup> Pursuant to Rule 416(a) under the Securities Act, this Registration Statement shall also cover any additional shares of the Registrant's common stock that become issuable in respect of the securities identified in the above table by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without the Registrant's receipt of consideration that increases the number of the outstanding shares of the Registrant's common stock. Represents additional shares of common stock reserved for issuance under the Registrant's 2016 Employee Stock Purchase Plan (the "2016 ESPP") resulting from the annual automatic increase in the number of authorized shares reserved for issuance under the 2016 ESPP. The increase was effective as of January 2, 2026. Estimated under Rules 457(c) and (h) of the Securities Act solely for the purpose of calculating the registration fee on the basis of the average of the high and low prices of the common stock as quoted by The Nasdaq Stock Market on February 23, 2026, which date is within five business days prior to the filing of the Registration Statement, multiplied by 85%, which is the percentage of the trading price per share applicable to purchasers under the 2016 ESPP.

---

| | |
|:---|:---|
| | |
| **Rule 457(p)** | **Rule 457(p)** |
| Fee Offset Claims | N/A |
| Fee Offset Sources | N/A |

---